Navigation Links
Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2008
Date:8/5/2008

MINNEAPOLIS, Aug. 5 /PRNewswire-FirstCall/ -- Techne Corporation's (Nasdaq: TECH) consolidated net earnings for the quarter ended June 30, 2008 increased 18.9% to $27.3 million or $.70 per diluted share compared with $22.9 million or $.58 per diluted share for the quarter ended June 30, 2007. For the fiscal year ended June 30, 2008, Techne's consolidated net earnings increased 21.7% to $103.6 million or $2.64 per diluted share compared with $85.1 million or $2.15 per diluted share for the fiscal year ended June 30, 2007.

Net earnings as a percentage of net sales improved to 40.2% for the fiscal year ended June 30, 2008 from 38.1% in the fiscal year ended June 30, 2007. The improvement in net earnings was mainly due to increased consolidated net sales. The favorable impact on consolidated net earnings of the change in exchange rates used to convert foreign currencies (primarily British pound sterling and Euros) to U.S. dollars was $296,000 ($.008 per diluted share) for the quarter and $1.3 million ($.034 per diluted share) for the fiscal year ended June 30, 2008.

Consolidated net sales for the quarter and fiscal year ended June 30, 2008 were $67.8 million and $257.4 million, respectively. This was an increase of 16.0% and 15.2% from the quarter and fiscal year ended June 30, 2007, respectively. Consolidated net sales were favorably affected by the strength of foreign currencies as compared to the U.S. dollar. Excluding the effect of changes in foreign currency exchange rates, consolidated net sales increased 12.1% and 12.3% for the quarter and fiscal year ended June 30, 2008, respectively, from the comparable prior year periods.

Biotechnology net sales, which include sales by R&D Systems' Biotechnology Division, R&D Systems China and BiosPacific, were $42.5 million and $165.7 million for the quarter and fiscal year ended June 30, 2008, increases of 11.6% and 13.0%, respectively, from the quarter and fiscal year ended June 30, 2007. This improvement was primarily the result of increased volume, including shipments to diagnostic customers. Increased sales to diagnostic customers positively effected Biotechnology net sales in the second and third quarters of fiscal 2008. The timing of diagnostic customer sales is not predictable and these sales increases are not necessarily indicative of future sales. Excluding sales to diagnostic customers, Biotechnology net sales increased 12.4% for the fiscal year ended June 30, 2008 from the comparable prior year period.

R&D Europe's net sales for the quarter and fiscal year ended June 30, 2008 were $21.0 million and $75.7 million, increases of 30.0% and 22.6%, respectively, from the same prior-year periods. R&D Europe's net sales increased 16.0% and 12.2% for the quarter and fiscal year ended June 30, 2008 when measured at currency rates in effect in the comparable prior periods.

Hematology net sales for the quarter and fiscal year ended June 30, 2008 were $4.2 million and $16.0 million, increases of 1.9% and 6.1%, respectively, compared to the quarter and fiscal year ended June 30, 2007. The increase for the fiscal year was mainly due to increased volume sales to several OEM customers during the third quarter of the fiscal year.

Consolidated gross margins were 79.5% for both the quarter and fiscal year ended June 30, 2008, compared to 78.3% and 79.1% for the quarter and fiscal year ended June 30, 2007, respectively. The gross margin improvement resulted from higher gross margins in Europe due to favorable exchange rates and changes in sales mix as a result of higher sales growth in the Biotechnology Division as compared to the sales growth in the lower margin Hematology Division. This improvement was partially offset by lower gross margins generated from high volume sales to diagnostic customers, particularly in the second and third quarters of the fiscal year.

Selling, general and administrative expenses for the quarter and fiscal year ended June 30, 2008 increased $1.1 million (14.6%) and $5.7 million (18.6%), respectively, from the same prior year periods. These increases include wage and salary increases and the hiring of additional marketing and administrative personnel to support the Company's sales growth. Selling, general and administrative expenses for the quarter ended June 30, 2008 also increased from the same prior year period due to increased profit sharing and bonuses of $841,000. Selling, general and administrative expenses for the fiscal year ended June 30, 2008 also increased because of additional profit sharing and bonuses of $2.0 million, increased legal fees of $837,000, R&D China selling, general and administrative expenses of $552,000, and the change in foreign currency exchange rates used to convert British pounds to U.S. dollars of $311,000.

The effective tax rates for both the quarter and fiscal year ended June 30, 2008 were 32.7% as compared to effective tax rates of 32.9% and 34.0% for the quarter and fiscal year ended June 30, 2007, respectively. Fiscal year 2008 rates were positively impacted by changes in state apportionment estimates. Without significant business developments, the Company expects its fiscal 2009 effective income tax rate to range from approximately 33.0% to 34.0%.

In November 2007, the Company's Board of Directors authorized the repurchase and retirement of up to $150 million of the Company's common stock. The Company repurchased approximately 140,000 shares of its common stock during the fourth quarter of fiscal 2008 for approximately $9.4 million. During fiscal 2008, the Company repurchased approximately 899,000 shares of its common stock for approximately $58.7 million.

Forward Looking Statements:

This earnings release contains forward-looking statements within the meaning of the Private Litigation Reform Act. These statements, including the Company's expectations as to and income tax rates, involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, the retention of hematology OEM and proficiency survey business, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in this release due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

* * * * * * * * * * * *

Techne Corporation has two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England. R&D Systems is a specialty manufacturer of biological products. R&D Systems has two subsidiaries, BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China. BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. R&D China and R&D Europe distribute biotechnology products.

TECHNE CORPORATION

CONSOLIDATED STATEMENTS OF EARNINGS

(In thousands, except per share data)

(Unaudited)

QUARTER ENDED FISCAL YEAR ENDED

6/30/08 6/30/07 6/30/08 6/30/07

Net sales $67,769 $58,425 $257,420 $223,482

Cost of sales 13,888 12,697 52,889 46,667

Gross margin 53,881 45,728 204,531 176,815

Operating expenses:

Selling, general

and administrative 8,986 7,839 36,715 30,965

Research and

development 5,812 5,014 22,394 20,082

Amortization of

intangible assets 282 404 1,135 1,614

Total operating

expenses 15,080 13,257 60,244 52,661

Operating income 38,801 32,471 144,287 124,154

Other expense (income):

Interest expense -- -- -- 1,083

Interest income (2,783) (2,565) (12,188) (8,434)

Other non-operating

expense, net 1,079 894 2,644 2,574

Total other income (1,704) (1,671) (9,544) (4,777)

Earnings before income

taxes 40,505 34,142 153,831 128,931

Income taxes 13,248 11,218 50,273 43,820

Net earnings $27,257 $22,924 $103,558 $85,111

Earnings per share:

Basic $0.70 $0.58 $2.65 $2.16

Diluted $0.70 $0.58 $2.64 $2.15

Weighted average common

shares outstanding:

Basic 38,665 39,444 39,139 39,406

Diluted 38,788 39,555 39,247 39,513

TECHNE CORPORATION

CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

ASSETS 6/30/08 6/30/07

Cash and equivalents $166,992 $135,485

Short-term available-for-sale investments 39,353 29,289

Trade accounts receivable 31,747 29,559

Other receivables 1,585 1,407

Inventory 9,515 8,757

Other current assets 9,241 8,341

Current assets 258,433 212,838

Available-for-sale investments 87,384 91,433

Property and equipment, net 101,722 91,535

Goodwill and intangible assets, net 29,032 30,167

Other non-current assets 30,798 28,871

Total assets $507,369 $454,844

LIABILITIES

Current liabilities $20,239 $17,193

Stockholders' equity 487,130 437,651

Total liabilities and equity $507,369 $454,844


'/>"/>
SOURCE Techne Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Techne Corporation Announces Share Repurchase Authorization
2. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008
3. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
6. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
7. BioElectronics Corporation Announces Singapore and Malaysia Sales
8. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
9. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
10. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
11. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... COPENHAGEN, Denmark , Feb. 3, 2016 ... stage biotechnology company that applies its innovative TransCon technology ... to present at an upcoming investor conference.Event:2016 Leerink Partners ... York, NY Date:  , Wednesday, February 10, 2016 Time:  ... --> www.ascendispharma.com . --> An audio ...
(Date:2/3/2016)... 3, 2016 New Jersey Health Foundation (NJHF) ... million for researchers in New Jersey ... that demonstrates exciting potential.   James ... the New Jersey Health Foundation Research Grant Program ... educational institutions— Princeton University, Rutgers University, Rowan University ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... series of potential targets (epitopes) specific to misfolded, propagating strains of Amyloid beta ... specific monoclonal antibody therapeutics for Alzheimer’s. , Following on from the first misfolded ...
(Date:2/3/2016)... (PRWEB) , ... February 03, 2016 , ... ... events annual report which summarizes and analyzes nearly 750 unique supply ... monitoring, alert, and analysis service. , Supply chain risk management practitioners subscribe ...
Breaking Biology Technology:
(Date:1/21/2016)... India , January 21, 2016 ... According to a new market research report "Emotion Detection ... and Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020", published by ... is expected to reach USD 22.65 Billion by ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
(Date:1/11/2016)... Jan. 11, 2016 Synaptics Incorporated (NASDAQ: ... today announced that its ClearPad ® TouchView ™ ... won two separate categories in the 8 th ... Best Technology Breakthrough. The Synaptics ® TDDI solution ... supply chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):